BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 35452851)

  • 1. Novel treatment strategies for acetylcholine receptor antibody-positive myasthenia gravis and related disorders.
    Mané-Damas M; Molenaar PC; Ulrichts P; Marcuse F; De Baets MH; Martinez-Martinez P; Losen M
    Autoimmun Rev; 2022 Jul; 21(7):103104. PubMed ID: 35452851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AChR-specific immunosuppressive therapy of myasthenia gravis.
    Luo J; Lindstrom J
    Biochem Pharmacol; 2015 Oct; 97(4):609-619. PubMed ID: 26215875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent approaches to the development of antigen-specific immunotherapies for myasthenia gravis.
    Lagoumintzis G; Zisimopoulou P; Kordas G; Lazaridis K; Poulas K; Tzartos SJ
    Autoimmunity; 2010 Aug; 43(5-6):436-45. PubMed ID: 20187712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conventional and emerging treatments and controversies in myasthenia gravis.
    Evoli A; Damato V
    Expert Rev Neurother; 2023 May; 23(5):445-456. PubMed ID: 37102669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia gravis. Update on diagnosis and therapy.
    García Estévez DA; Pardo Fernández J
    Med Clin (Barc); 2023 Aug; 161(3):119-127. PubMed ID: 37248131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
    Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
    J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
    Beecher G; Putko BN; Wagner AN; Siddiqi ZA
    Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.
    Lindstrom JM; Engel AG; Seybold ME; Lennon VA; Lambert EH
    J Exp Med; 1976 Sep; 144(3):739-53. PubMed ID: 182897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathogenic antibodies in myasthenia gravis].
    Motomura M
    Brain Nerve; 2010 Apr; 62(4):411-8. PubMed ID: 20420182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic options in autoimmune myasthenia gravis.
    García-Carrasco M; Escárcega RO; Fuentes-Alexandro S; Riebeling C; Cervera R
    Autoimmun Rev; 2007 Jun; 6(6):373-8. PubMed ID: 17537383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis. Pathogenesis and current concepts in management.
    Havard CW; Scadding GK
    Drugs; 1983 Aug; 26(2):174-84. PubMed ID: 6884241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc-Receptor Targeted Therapies for the Treatment of
    Keller CW; Pawlitzki M; Wiendl H; Lünemann JD
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071155
    [No Abstract]   [Full Text] [Related]  

  • 15. Myasthenia and the neuromuscular junction.
    Gilhus NE
    Curr Opin Neurol; 2012 Oct; 25(5):523-9. PubMed ID: 22892950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis with anti-acetylcholine receptor antibodies.
    Meriggioli MN
    Front Neurol Neurosci; 2009; 26():94-108. PubMed ID: 19349707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of novel therapies for MG: Studies in animal models.
    Souroujon MC; Brenner T; Fuchs S
    Autoimmunity; 2010 Aug; 43(5-6):446-60. PubMed ID: 20298126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal Antibody-Based Therapies for Myasthenia Gravis.
    Alabbad S; AlGaeed M; Sikorski P; Kaminski HJ
    BioDrugs; 2020 Oct; 34(5):557-566. PubMed ID: 32915379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of myasthenia gravis.
    Arora Y; Li Y
    Hosp Pract (1995); 2013; 41(4):40-50. PubMed ID: 24145588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcholine receptors and myasthenia.
    Lindstrom JM
    Muscle Nerve; 2000 Apr; 23(4):453-77. PubMed ID: 10716755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.